

The Innovative Medicines Initiative (IMI)



Research Agenda Scientific Priorities for 2008 Call Topics for 2008

IMI Member States Group Meeting March 26th, 2008

Karima Boubekour, PhD, MBA

F. Hoffmann-La Roche Ltd



Objectives of this presentation




-
- Present background on the development of the first IMI Call
 - Give an overview of the proposed Call Topics for 2008
 - Answer questions from the Member States Group on the process and rationale for these topics




- Prepared following extensive consultation of all relevant stakeholders
- Identifies pre-competitive bottlenecks in the R&D process
- Proposes recommendations to address these bottlenecks

Pre-Competitive Bottlenecks in the R&D Process



IMI Research Agenda is Focusing on 5 Disease Areas



IMI Call 2008 Process



- ✓ Format agreed upon with DG Research in 2007
- ✓ Topics selected based on:
 - ✓ Number of EFPIA companies interested
 - ✓ Existing leadership
 - ✓ Clarity concerning the contribution of EFPIA participants
- ✓ Prepared by over 150 experts from 24 companies
- ✓ Extensively discussed and approved by EFPIA RDG
- ✓ Improved based on input from FP experts from DG Research
- ✓ Additional input provided by DG Information Society and DG Enterprise at a meeting on February 14th, 2008

Description of the Call Topics



1. Title
2. Project description
3. Key deliverables of the project
4. EFPIA participants in the projects
5. Role of EFPIA participants in the projects
6. Duration of the project
7. In kind contribution from the EFPIA companies
8. Expectations from the applicant consortium

Proposed IMI Call 2008



IMI Call Topics 2008
Version of 27/02/2008

Table of Content

| | |
|--|----|
| Introduction..... | 3 |
| IMI Safety Pillar..... | 4 |
| 1. Improve Predictivity of Immunogenicity..... | 4 |
| 2. Non-genotoxic Carcinogenesis..... | 11 |
| 3. Expert Systems for <i>in silico</i> Toxicity Prediction..... | 17 |
| 4. Improved Predictivity of non-clinical Safety Evaluation..... | 22 |
| 5. Qualification of Translational Safety Biomarkers..... | 27 |
| 6. Strengthening the Monitoring of Benefit/Risk..... | 34 |
| IMI Efficacy Pillar..... | 38 |
| 7. Islet Cell Research..... | 38 |
| 8. Surrogate Markers for Vascular Endpoints..... | 44 |
| 9. Pain Research..... | 51 |
| 10. New Tools for the Development of Novel Therapies In Psychiatric Disorders..... | 58 |
| 11. Neurodegenerative Disorders..... | 63 |
| 12. Understanding Severe Asthma..... | 69 |
| 13. COPD Patient Reported Outcomes..... | 74 |
| IMI Education & Training Pillar..... | 81 |
| 14. European Medicines Research Training Network..... | 81 |
| 15. Safety Sciences for Medicines Training Programme..... | 84 |
| 16. Pharmaceutical Medicine Training Programme..... | 88 |
| 17. Integrated Medicines Development Programme..... | 93 |
| 18. Pharmacovigilance Training Programme..... | 97 |

- Consists of 18 Topics
- Based on 3/4 pillars from the Research Agenda:
 - Safety,
 - Efficacy,
 - Education & Training
- Covers 3/5 disease areas:
 - Metabolic
 - Brain
 - Inflammatory

IMI Call 2008

Call Topics



- ✓ 5 safety prediction
- ✓ 1 pharmacovigilance
- ✓ 2 diabetes
- ✓ 3 brain disorders
- ✓ 2 respiratory diseases
- ✓ 5 education & training

High Company Support and proposed in kind contribution



| | | |
|---|----------------------|---------------------|
| Immunogenicity | €13 between | 11 companies |
| Non-genotoxic carcinogens | €2.5 between | 8 companies |
| In silico expert systems | €5 between | 9 companies |
| Predictivity of non-clinical Safety | €10 between | 11 companies |
| Translational safety biomarkers | €21 between | 11 companies |
| Pharmacovigilance | €15 between | 14 companies |
| Islet cell research | €10 between | 10 companies |
| Surrogate markers for vascular endpoints | €20 between | 7 companies |
| Pain Research | €7.5 between | 12 companies |
| Psychiatric disorders | €10 between | 12 companies |
| Neurodegenerative disorders | €7.5 between | 14 companies |
| Severe Asthma | €12.5 between | 8 companies |
| COPD | €2 between | 9 companies |
| Education & Training | €18.5 between | 24 companies |

The Innovative Medicines Initiative (IMI)



Thank you very much